Related Experiment Video

Updated: Sep 7, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.4K

Combination Therapies for Advanced Hepatocellular Carcinoma: Biomarkers and Unmet Needs

Sarah Cappuyns1,2, Josep M Llovet1,3,4

  • 1Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 21, 2022
PubMed

Insights

New treatments combining PD(L)1 inhibitors and anti-VEGFA therapy are revolutionizing advanced hepatocellular carcinoma (HCC) care. Identifying biomarkers to predict patient response remains a critical unmet need in clinical practice.

Area of Science:

  • Hepatobiliary cancers
  • Immunotherapy
  • Vascular biology

Background:

  • Advanced hepatocellular carcinoma (HCC) treatment has been transformed by combined PD(L)1 pathway inhibitors and anti-VEGFA therapy.
  • Predictive biomarkers for response to these novel therapies are currently lacking.
  • This deficiency presents a significant clinical challenge in optimizing patient selection and treatment strategies.

Purpose of the Study:

  • To address the critical need for biomarkers predictive of response to combined PD(L)1 and anti-VEGFA therapy in advanced HCC.
  • To identify potential indicators that can guide clinical decision-making for this revolutionary treatment approach.

Main Methods:

  • This study focuses on identifying predictive biomarkers for response to combined immunotherapy and anti-angiogenic therapy in advanced HCC.
  • Methods involve analyzing patient data and molecular profiles to uncover response predictors.

Main Results:

  • The study investigates the efficacy of novel therapeutic combinations in advanced HCC.
  • Key findings relate to the identification of potential biomarkers that correlate with treatment response.

Conclusions:

  • The development of predictive biomarkers is essential for personalizing treatment with PD(L)1 inhibitors and anti-VEGFA therapy in advanced HCC.
  • Further research is needed to validate these biomarkers and improve patient outcomes.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
656
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K